Biodexa Pharmaceuticals (NASDAQ:BDRX) Shares Scheduled to Reverse Split on Monday, April 6th

Shares of Biodexa Pharmaceuticals PLC Unsponsored ADR (NASDAQ:BDRX) are set to reverse split on the morning of Monday, April 6th. The 1-5 reverse split was announced on Wednesday, March 18th. The number of shares owned by shareholders will be adjusted after the market closes on Friday, April 3rd.

Biodexa Pharmaceuticals Price Performance

Shares of NASDAQ BDRX opened at $0.70 on Friday. The business has a 50-day moving average price of $1.40 and a 200 day moving average price of $4.08. Biodexa Pharmaceuticals has a 52-week low of $0.68 and a 52-week high of $19.40.

Analyst Ratings Changes

BDRX has been the topic of a number of research reports. Wall Street Zen lowered shares of Biodexa Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Saturday, March 14th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Biodexa Pharmaceuticals in a research note on Monday, December 29th. One investment analyst has rated the stock with a Sell rating, According to MarketBeat, the company presently has an average rating of “Sell”.

Institutional Investors Weigh In On Biodexa Pharmaceuticals

A hedge fund recently bought a new stake in Biodexa Pharmaceuticals stock. Armistice Capital LLC purchased a new position in shares of Biodexa Pharmaceuticals PLC Unsponsored ADR (NASDAQ:BDRX) during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor purchased 100,000 shares of the company’s stock, valued at approximately $227,000. Armistice Capital LLC owned 14.71% of Biodexa Pharmaceuticals as of its most recent SEC filing. 17.51% of the stock is owned by institutional investors and hedge funds.

Biodexa Pharmaceuticals Company Profile

Biodexa Pharmaceuticals Plc, a clinical stage biopharmaceutical company, focuses on developing a pipeline of products for the treatment of Type 1 diabetes and rare/orphan cancers of the brain. Its lead product candidate Tolimidone, a selective activator of the lyn kinase enzyme, currently under Phase II studies for the treatment of Type 1 diabetes. The company is also developing MTX110, which is currently in Phase I studies for the treatment of diffuse intrinsic recurrent glioblastoma, diffuse midline glioma, and medulloblastoma; and MTD217, a program centered around a water-soluble drug formulation that can be easily infused or injected simultaneously, or sequentially, directly into the cancer microenvironment, currently under preclinical studies for the treatment of leptomeningeal disease.